 |
- goat polyclonal IgG, 200 µg/ml
- epitope mapping within an internal region of A20 of human origin
- recommended for detection of A20 of human origin by WB, IP, IF and ELISA
- blocking peptide, sc-32525 P
- TransCruz reagent for Gel Supershift and ChIP applications, sc-32525 X, 200 µg/0.1 ml
|
|
| |
Ordering Information
Recommended Support Products:
(click button of application of choice)
| |
| Species |
Gene Name |
Gene ID |
Chromosome Location |
Isoform (mRNA) Accession # |
Protein Accession # |
OMIM™ Number |
| Human |
TNFAIP3 |
7128 |
6q23.3 |
NM_006290 |
P21580
|
191163 |
| |
A20 Background Information A20 is a Cys2/Cys2 zinc finger protein that is induced by a variety of inflammatory stimuli and regulates gene expression. Specifically, A20 is induced by tumor necrosis factor (TNF) and interleukin 1 (IL-1), and acts as a negative regulator of nuclear factor ˚ B (NF˚B) gene expression. By inhibiting NF˚B activation, A20 plays a critical role in terminating NF˚B responses to various stimuli. Although the C-terminal region of A20 contains seven zinc finger domains, only four of these domains are required for in vitro inhibition of TNF-induced NF˚B activation. A20 also interacts with several other proteins, such as TRAF2, TRAF6 and IkB kinase (IKK) © protein, and can thereby inhibit cell death. TXBP151, a novel A20-binding protein, may mediate the anti-apoptotic activity of A20. Involved in the negative feedback regulation of signal transduction, A20 and A20-binding proteins may be useful as novel therapeutic tools in the treatment of a variety of diseases. |
 |
|
A20 (A-15)
Click on image to enlarge
|
|
A20 (A-15): sc-32525. Western blot analysis of A20 expression in Daudi (A), Jurkat (B), TNFα-treated Jurkat (C) and TNFα-treated U-937 (D) whole cell lysates.
|
|
Download
|
|